Pediatr. praxi. 2012;13(6):388-390

Inflammatory bowel disease in children

MUDr.Katarína Mitrová
Oddělení dětské gastroenterologie, Pediatrická klinika 2. LF UK a FN Motol, Praha

Inflammatory bowel disease (IBD) is a group of chronic, immune-mediated diseases primarily affecting the gastrointestinal tract. IBD includes

Crohn‘s disease, ulcerative colitis and indeterminate colitis. IBD can be painful and debilitating disease affecting child’s nutritional status.

Early diagnosis and optimal therapy can significantly change the course of the disease and ensure optimal child’s growth and development.

Keywords: Crohn’s disease, ulcerative colitis, abdominal pain, weight loss, growth failure

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mitrová K. Inflammatory bowel disease in children. Pediatr. praxi. 2012;13(6):388-390.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Van Assche G, Dignass A, Panes J, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence - based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010; 4(1): 7-27. Go to original source... Go to PubMed...
    2. Sandhu BK, Fell JM, Beattie RM, et al. on Behalf of the IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition: Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom. J Pediatr Gastroenterol Nutr. 2010; 50: S1-S13. Go to original source... Go to PubMed...
    3. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory Bowel Disease in Children and Adolescents: Recommendations for Diagnosis-The Porto Criteria. J Pediatr Gastroenterol Nutr. 2005; 41(1): 1-7. Go to original source... Go to PubMed...
    4. de Bie CI, Buderus S, Sandhu BK, et al. Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. J Pediatr Gastroenterol Nutr. 2012; 54(3): 374-380. Go to original source... Go to PubMed...
    5. Weinstein TA, Levine M, Pettei MJ, et al. Age and family history at presentation of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2003; 37(5): 609-613. Go to original source... Go to PubMed...
    6. Logan R, et al. Faecal calprotectin for the diagnosis of inflammatory bowel disease. BMJ 2010; 15, 341: c3636. Go to original source... Go to PubMed...
    7. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Feb 16. doi: 10.1002/ibd.22917. [Epub ahead of print]. Go to original source... Go to PubMed...
    8. Horsthuis K, de Ridder L, Smets AM, et al. Magnetic resonance enterography for suspected inflammatory bowel disease in a pediatric population. J Pediatr Gastroenterol Nutr. 2010; 51(5): 603-609. Go to original source... Go to PubMed...
    9. Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006; 21(10): 1609-1614. Go to original source... Go to PubMed...
    10. Critch J, Day AS, Otley A, et al on behalf of the NASPGHAN IBD Committee. Use of Enteral Nutrition: for the control of intestinal inflamation in Peadiatric Crohn Disease: J Pediatr Gastroenterol Nutr. 2012; 54(2): 298-305. Go to original source... Go to PubMed...
    11. Sherlock ME, Griffiths AM. Medical therapy for pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2012; 14(2): 166-173. Go to original source... Go to PubMed...
    12. Travis SP, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2(1): 24-62. Go to original source... Go to PubMed...
    13. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab the rapy for the treatment of moderatetose vere Crohn's disease in children. Gastroenterology 2007; 132(3): 863-873. Go to original source... Go to PubMed...
    14. Hyams J, Damaraju L, Blank M, et al. Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2011 [Epub ahead of print].
    15. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011; 106(2): 214-223. Go to original source...
    16. Wilson D, Thomas A, Croft N, et al. and the IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition: Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2010; 50: S14-S34. Go to original source... Go to PubMed...
    17. Hyams J, Griffiths AM, Markowitz J, et al. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children. J Crohn Colitis 2011; 5: S5-7. Go to original source...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.